F1 BioVentures

Investment decisions are made by Managing Partner Jeffrey Steinberg and Partner Edwin Kim. Steinberg's background is in healthcare equity research, while Kim formerly worked in pharmaceutical R&D at Merck. The firm runs a lean partnership structure where both principals directly underwrite each deal.

F1 BioVentures focuses on seed and Series A investments in preclinical and early clinical-stage biotechnology companies. The firm looks for capital-efficient programs that can achieve human proof-of-concept within initial syndicated financings, often as the first institutional investor in a round.

The firm's investment footprint is concentrated in North American biotechnology hubs, drawing deal flow from academic medical centers and life-science incubators. There is no public record of dedicated international investment activity. The sole office is in West Palm Beach, Florida.

F1 BioVentures operates a Principal-led partnership where the two named partners personally underwrite each investment, a structure uncommon at larger multi-stage biotech platforms. Steinberg's equity-analyst background also introduces a public-market narrative filter during evaluation, which some larger, science-first funds may apply later or not at all.

The firm's board posture has not been disclosed publicly. In typical early-stage biotech venture, lead seed investors often take board observer or director roles, but F1 BioVentures' specific governance practice cannot be confirmed from available public record.